With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...

The study of GLP1R variants shows associations with cardiometabolic traits and behavioral changes, highlighting indirect effects of GLP1RA on mental health.